Thrombosis in cancer patients: Etiology, incidence, and management

Rahul A. Sheth, Andrew Niekamp, Keith B. Quencer, Fadi Shamoun, Martha Gracia Knuttinen, Sailendra Naidu, Rahmi Oklu

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE.

Original languageEnglish (US)
Pages (from-to)S178-S185
JournalCardiovascular Diagnosis and Therapy
StatePublished - Dec 1 2017


  • Anticoagulation
  • Cancer
  • Venous access catheters
  • Venous thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Thrombosis in cancer patients: Etiology, incidence, and management'. Together they form a unique fingerprint.

Cite this